Sustained humoral response 6 months after the anti-SARS-CoV-2 mRNA-BNT162b2 vaccine in haemodialysis patients: should booster vaccine doses be given to all patients at the same time?
- Resource Type
- Article
- Authors
- Milia, Vincenzo La; Tonolo, Silvia; Luzzaro, Francesco; Bonato, Claudio; Limardo, Monica; Longhi, Selena; Ravasi, Chiara; Viganò, Sara; Cavalli, Andrea
- Source
- Clinical Kidney Journal. May2022, Vol. 15 Issue 5, p1012-1014. 3p.
- Subject
- *BOOSTER vaccines
*HEMODIALYSIS patients
*HUMORAL immunity
*SARS-CoV-2
- Language
- ISSN
- 2048-8505
In haemodialysis (HD) patients persistent seroconversion (PSC) was found 6 months after natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [[1]] and in 71-98% of patients after complete vaccination [[2]]. (A) All patients (r2 = 0.01); (B) patients without seroconversion 6 months after the second dose vaccine administration (r2 = 0.25); (C) patients with seroconversion 6 months after the second dose vaccine administration (r2 = 0.09); (D) patients with seroconversion 6 months after the second dose vaccine administration and IgG anti-SARS-CoV-2 positive at administration of first vaccine dose (r2 = 0.004). [Extracted from the article]